Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
10:16pm, Thursday, 14'th Jul 2022 Zacks Investment Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $81.91, marking a +1.5% move from the previous day.
Bear Market Winners: 3 Healthcare Stocks That Have Soared More Than 30% This Year
02:45pm, Thursday, 14'th Jul 2022 The Motley Fool
Have these scorching-hot stocks peaked, or could there still be more gains ahead for investors who buy today?
6 Cathie Wood Stocks to Buy on the Dip
11:21am, Thursday, 14'th Jul 2022
As major holdings in her portfolios, these Cathie Wood stocks to buy on the dips are likely to significantly pop when the market recovers. The post 6 Cathie Wood Stocks to Buy on the Dip appeared firs
The Best 3 Stocks in Cathie Wood's Ark ETF Have 1 Thing in Common
03:37pm, Wednesday, 13'th Jul 2022 The Motley Fool
They are also outperforming the S&P 500.
This Company Could Ease the Pain in a Bear Market
02:23pm, Saturday, 09'th Jul 2022 The Motley Fool
New product candidates aim to diversify into areas with a large unmet medical need.
3 No-Brainer Stocks to Buy in July
10:08am, Saturday, 09'th Jul 2022 The Motley Fool
These stocks appear to be clear winners.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
10:15pm, Friday, 08'th Jul 2022 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) closed at $76.70 in the latest trading session, marking a -1.92% move from the prior day.
7 Moonshot Investments Upending a $10 Trillion Industry
03:53pm, Friday, 08'th Jul 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on
Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug
03:48pm, Friday, 08'th Jul 2022 Zacks Investment Research
Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.
Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week
02:01pm, Friday, 08'th Jul 2022 The Motley Fool
These high-tech biotech stocks made a sharp U-turn this week after a rough start to the year.
This Hot Growth Stock Is Still a Buy After Enormous Gains
10:15am, Friday, 08'th Jul 2022 The Motley Fool
This biotech stock is worth holding onto for a while.
Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week
10:01am, Friday, 08'th Jul 2022
These high-tech biotech stocks made a sharp U-turn this week after a rough start to the year.
Want to Beat the Bear Market? Try These 2 Stocks
10:00am, Friday, 08'th Jul 2022 The Motley Fool
There's plenty of growth ahead for these companies.
7 Best Biotech Stocks to Buy in July 2022
07:35am, Friday, 08'th Jul 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. The post 7 Best Biotech Stocks to Buy in July 2022 appeared
Time To Board The ARKK
06:53am, Friday, 08'th Jul 2022 Seeking Alpha
Yesterday I made a call that the Market bottomed on 6/16. Barchart's Trend Spotter has moved from Sell to Hold on ARKK.
